Head and Neck Cancer Clinical Trial
Official title:
A Phase I Dose Escalation Study of Pemetrexed in Patients With Advanced Head and Neck Squamous Cell Cancer
Primary Objective:
- To determine the maximum tolerated doses (MTDs) of pemetrexed when given with
dexamethasone. (Please note: One of the three treatment groups will not receive
dexamethasone)
Secondary Objectives:
- To assess dose limiting toxicity (DLT), which is defined as grade 4 neutropenia > 7
days duration, neutropenic fever, grade 4 thrombocytopenia, or any grade 3 or 4
non-hematologic toxicity excluding nausea/vomiting and excluding grade 3 transaminase
toxicity.
- To determine objective response rate, as defined as complete response (CR) or partial
response (PR), confirmed by 2 CT scans at least 6 weeks apart in patients treated with
pemetrexed as a single agent with advanced squamous cell carcinoma of the head and
neck.
Pemetrexed is designed to block enzymes in the body that are important for tumor growth.
If you are found to be eligible to take part in this study, you will be assigned to one of 3
groups. All participants will receive pemetrexed once every 3 weeks through a needle in the
vein over about 10 minutes. Every 3 weeks is considered 1 cycle. Participants in Group 1
will receive pemetrexed only. Participants in Group 2 will also receive dexamethasone on Day
1 of each cycle through a needle in the vein. Participants in Group 3 will take
dexamethasone by mouth the day before, the day of, and the day after receiving pemetrexed.
Three (3) different dose levels of pemetrexed will be studied. The first group of 6
participants will be treated at Dose Level 1 (lowest of the 3 doses) and evaluated for 3
weeks. If 0 or 1 out of 6 participants experience severe side effects at Dose Level 1, the
next group of 6 participants will be treated at Dose Level 2. At any given dose, if greater
than 1 out of 6 participants experience severe side effects, then no further participants
will receive that dose or a higher dose.
Every 3 weeks (each cycle), you will have a physical exam, including measurement of vital
signs (temperature, pulse, breathing rate, and blood pressure) and weight. Blood (about 3-4
teaspoons) will be collected for routine tests. A performance status evaluation (a test
looking at the ability to perform everyday activities) and a liver function test will also
be done. Your tumor will be evaluated by CT scan and chest x-ray every 2 cycles of study
treatment.
While on study, you will be required to take folic acid by mouth every day for 5-7 days
before the first dose of pemetrexed and continuing until 3 weeks after your last dose of
pemetrexed. You will also receive an injection of vitamin B12 into your muscle 1 to 2 weeks
before your first dose of pemetrexed. The vitamin B12 injection will be repeated every 9
weeks until 3 weeks after your last dose of pemetrexed. It is very important that folic acid
and vitamin B12 be given to decrease the risk of severe side effects from the pemetrexed.
You may receive up to 6 cycles of treatment. You will be taken off study if the disease gets
worse or intolerable side effects occur. When you stop taking study drug on this study, you
will have a physical exam, including measurement of vital signs (temperature, pulse,
breathing rate, and blood pressure) and weight. Blood (about 3-4 teaspoons) will be
collected for routine tests. A performance status evaluation (a test looking at the ability
to perform everyday activities) and a liver function test (about 1-2 teaspoons of blood)
will also be done.
After completion of 6 cycles of treatment, you will be asked to return to the clinic for
follow-up visits every 2-3 months for standard follow-up.
This is an investigational study. The FDA has approved pemetrexed for the treatment of
non-small cell lung cancer. However, the FDA has authorized pemetrexed for research only in
the patients with HNSCC. Between 40-50 patients will take part in this study. All will be
enrolled at M. D. Anderson.
;
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05808920 -
The RESCUE Study: Survival and Functional Outcomes Following Salvage Surgery for RESidual or reCurrent sqUamous cEll Carcinoma of the Head and Neck
|
||
| Completed |
NCT02526017 -
Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers
|
Phase 1 | |
| Active, not recruiting |
NCT05060432 -
Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
| Recruiting |
NCT03997643 -
Preservation of Swallowing in Respected Oral Cavity Squamous Cell Carcinoma: Examining Radiation Volume Effects (PRESERVE): A Randomized Trial
|
Phase 2 | |
| Active, not recruiting |
NCT03170960 -
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
| Recruiting |
NCT04700475 -
Effect of Low Level Laser Therapy on Prevention of Radiotherapy Induced Xerostomia in Cancer Patients.
|
N/A | |
| Withdrawn |
NCT04058145 -
AMD3100 Plus Pembrolizumab in Immune Checkpoint Blockade Refractory Head and Neck Squamous Cell Carcinoma
|
Phase 2 | |
| Completed |
NCT02572869 -
Functional and Aesthetic Outcomes After Mandible Reconstruction With Fibula Osteomyocutaneous Free Flaps
|
||
| Active, not recruiting |
NCT04474470 -
A Study to Evaluate NT219 Alone and in Combination With ERBITUX® (Cetuximab) in Adults With Advanced Solid Tumors and Head and Neck Cancer
|
Phase 1/Phase 2 | |
| Withdrawn |
NCT05073809 -
Photoacoustic Imaging of Head and Neck Tumours
|
||
| Active, not recruiting |
NCT04383210 -
Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors
|
Phase 2 | |
| Active, not recruiting |
NCT03651570 -
Randomized Controlled Trial of a E-intervention to Help Patients Newly Diagnosed With Cancer Cope Better: Pilot Study
|
N/A | |
| Recruiting |
NCT04930432 -
Study of MCLA-129, a Human Bispecific EGFR and cMet Antibody, in Patients With Advanced NSCLC and Other Solid Tumors
|
Phase 1/Phase 2 | |
| Recruiting |
NCT06016699 -
Immunological Function After Radiation With Either Proton or Photon Therapy
|
||
| Terminated |
NCT03843554 -
Commensal Oral Microbiota in Head and Neck Cancer
|
N/A | |
| Recruiting |
NCT05915572 -
Mulligan Technique on Shoulder Dysfunction
|
N/A | |
| Completed |
NCT05897983 -
Tens and Rocabado Exercises on TMJ Dysfunction
|
N/A | |
| Not yet recruiting |
NCT06289049 -
Heavy Strength Training in Head and Neck Cancer Survivors
|
Phase 2 | |
| Withdrawn |
NCT05263648 -
Virtual Reality Software to Reduce Stress in Cancer Patients
|
N/A | |
| Withdrawn |
NCT03238638 -
A Study of Epacadostat + Pembrolizumab in Head and Neck Cancer Patients, Who Failed Prior PD-1/PD-L1 Therapy
|
Phase 2 |